High-certainty evidence supports low-dose colchicine in reducing myocardial infarction and stroke risk in patients with established cardiovascular disease.
No increase in serious adverse events was observed, but gastrointestinal side effects were more common.
No significant reduction in all-cause or cardiovascular mortality, or coronary revascularisation rates.
Further research is needed to clarify benefits in specific subgroups and long-term use in stable coronary artery disease.
